Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia-Reference-Cited by-同舟云学术

Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia

Published:2020-12 Issue:6 Volume:38 Page:872-890.e6
ISSN:1535-6108
Container-title:Cancer Cell
language:en
Short-container-title:Cancer Cell

Author:

Bhatt Shruti,Pioso Marissa S.,Olesinski Elyse Anne,Yilma Binyam,Ryan Jeremy A.,Mashaka Thelma,Leutz Buon,Adamia Sophia,Zhu Haoling^ORCID,Kuang Yanan,Mogili Abhishek^ORCID,Louissaint Abner,Bohl Stephan R.,Kim Annette S.,Mehta Anita K.,Sanghavi Sneha^ORCID,Wang Youzhen,Morris Erick,Halilovic Ensar,Paweletz Cloud P.,Weinstock David M.^ORCID,Garcia Jacqueline S.,Letai Anthony

Funder

National Institutes of Health

Publisher

Elsevier BV

Subject

Cancer Research,Cell Biology,Oncology

Reference58 articles.

1. Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia;Blombery;Cancer Discov.,2019

2. MCL-1-dependent leukemia cells are more sensitive to chemotherapy than BCL-2-dependent counterparts;Brunelle;J. Cell Biol.,2009

3. AMG 176, a selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies;Caenepeel;Cancer Discov.,2018

4. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members;Certo;Cancer Cell,2006

5. Targeting mitochondrial structure sensitizes acute myeloid leukemia to venetoclax treatment;Chen;Cancer Discov.,2019

Cited by 93 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CRISPR screen of venetoclax response-associated genes identifies transcription factor ZNF740 as a key functional regulator;Cell Death & Disease;2024-08-27

2. BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models;Nature Cancer;2024-08-23

3. Venetoclax resistance leads to broad resistance to standard-of-care anti-MM agents, but not to immunotherapies;Blood Advances;2024-07-29

4. Apoptotic signaling pathways in bone metastatic lung cancer: a comprehensive analysis;Discover Oncology;2024-07-26

5. Profiling protein–protein interactions to predict the efficacy of B-cell-lymphoma-2-homology-3 mimetics for acute myeloid leukaemia;Nature Biomedical Engineering;2024-07-18